These results suggest that BCL6B hypermethylation promotes tumor onset and progression; these abnormally methylated CpG units in the BCL6B promoter region might serve as novel methylation markers for diagnosis of the lung cancer. The gene discussed is BCL6B; the disease is lung carcinoma.